Rituximab for autoimmune blistering diseases: recent studies, new insights.
Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affect response to rituximab, and the efficacy and safety of rituximab in autoimmune blistering diseases, incorporating recent data on the use of rituximab in other autoimmune disease patients.
Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
L
L
Lunardon
A S
AS
Payne
D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D004351:Drug Resistance; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D010392:Pemphigus / Q000188:drug therapy; D000069283:Rituximab; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy*
D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab